The Tachi Ya­ma­da lega­cy tree con­tin­ues to grow with a new gene edit­ing biotech from Jim Wil­son

Jim Wil­son has been busy late­ly.

Back in May, the AAV pi­o­neer from the Uni­ver­si­ty of Penn­syl­va­nia launched a sec­ond-gen­er­a­tion gene ther­a­py biotech, G2 Bio Com­pa­nies, and just last week un­veiled a non­prof­it aim­ing to serve rare dis­ease pop­u­la­tions where the phar­ma mod­el pro­vides lit­tle eco­nom­ic in­cen­tive. Both ef­forts saw sig­nif­i­cant in­volve­ment from the late Tachi Ya­ma­da, who con­tin­ues to in­spire those work­ing at his lega­cy star­tups.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER